ISPUB.com / IJDS/2/2/6463
  • Author/Editor Login
  • Registration
  • Facebook
  • Google Plus

ISPUB.com

Internet
Scientific
Publications

  • Home
  • Journals
  • Latest Articles
  • Disclaimers
  • Article Submissions
  • Contact
  • Help
  • The Internet Journal of Dental Science
  • Volume 2
  • Number 2

Original Article

The Role Of Human Papillomavirus (HPV) And The Increasing Incidence Of Oral Pathology In The Era Of Highly Active Antiretroviral Therapy (HAART)

K Shetty, J Leigh

Keywords

antiretrovirals, hiv, human papilloma virus, pathology

Citation

K Shetty, J Leigh. The Role Of Human Papillomavirus (HPV) And The Increasing Incidence Of Oral Pathology In The Era Of Highly Active Antiretroviral Therapy (HAART). The Internet Journal of Dental Science. 2004 Volume 2 Number 2.

Abstract

Oral HPV infection and disease results from increases in oral-based immune suppression in the HIV co-infected individual that cannot be restored and is possibly compromised further by HAART. This review provides greater insight into the rate of oral HPV infection in the HIV+ individual, the effect of HAART on oral HPV infection, it's role in oral pathology, and the host's immune response against HPV under immune compromised (HIV without effective HAART) and potentially immune restored (effective HAART) conditions.

 

Introduction

The human immunodeficiency virus (HIV) epidemic continues to grow at a significant rate worldwide with over 34 million people infected1. This disease leads to progressive immune suppression with selective depletion of CD4+ T lymphocytes. There are numerous opportunistic infections that occur secondary to this decrease in systemic immunity, particularly in the oral cavity with over 50% of HIV-infected individuals developing oral pathology2. One pathogen which is commonly found in both the oral and genital tracts of HIV-positive patients is the mucosatropic human papillomavirus (HPV), however infection can occur with or without mucosal pathology3,4. HPV-associated oral lesions include condyloma, focal epithelial and some squamous cell carcinomas4, 5. Both oral and genital lesions caused by HPV are more commonly seen in those co-infected with HIV6,7,8. Systemic immune reconstitution for the HIV-positive patient has been accomplished with highly active anti-retroviral therapy (HAART) leading to decreases in systemic and oral infections, including regression in HPV-induced cervical lesions9, 10. Paradoxically, recent reports have noted increases in oral pathology consistent with HPV infection in the presence of HAART12, 13. If this observation can be confirmed, it suggests that the host defense against oral HPV is independent of that restored by HAART and may be adversely affected. Unfortunately, little is known about the prevalence, natural history and immune response against oral HPV infection, especially in the HIV co-infected individual.

Human Papillomavirus In Oral Disease

Seventy types of human papillomavirus (HPV) have been described with types divided by site of infection and their risk oncogenic potential (see table 1)15. HPV is associated with several oral lesions compatible with oral warts (veruca vulgaris, squamous cell papillomas, condyloma acuminata, focal epithelial hyperplasia (FEH) and also oral leukoplakia with dysplastic changes4, 5. Such lesions have been reported in 0.4% of the general population16,17, however, the HPV DNA detection rate in individuals without any obvious oral pathology has varied widely depending on the study population, type of sample collected, method of DNA detection (hybridization vs. PCR), and the primers and specific probes utilized5,18,19,20,21. HPV is also thought to play a role in the genesis of oral cancers22,23,24,25 with HPV DNA, particularly type 16 and 18, detected in 20-30% of oral squamous cell carcinomas (SCC)26,27. What is lacking in these studies is a detailed analysis of the exact site of HPV oral infection as well as detailed delineation of the role of HPV in abnormal or cancerous oral tissue.

HPV in HIV Disease.

As with the HIV- population there are large differences between the infection rates with HPV and the occurrence of oral lesions28,29,30, however, these HPV associated lesions occur more commonly under conditions of immune suppression31, 32, 33. In addition, oral lesions similar to those seen in HIV- individuals contain additional or novel HPV types in a significant subpopulation. (2.5-4% of HIV+ patients)6. Greenspan et al have described cauliflower and spiky warts containing HPV type 7 and flat warts, similar in appearance to FEH, containing HPV 13,18 and 3234,35. A study of benign oral lesions, not restricted to warts, Volter et al found HPV DNA sequences in 67% of the specimens27. The most common types found were HPV 32 (28%) and HPV 7 (19%), which would have been missed if testing only for genital HPV types. A study on oral squamous cell carcinomas in HIV+ individuals have demonstrated an early age of onset, an aggressive course, and a high rate of HPV DNA detection36.

Comparative studies have shown that HPV infection is increased in the HIV+ individual as demonstrated by Coutlee et al where HPV DNA was detected in 2.6% of the oral cavities of HIV- adults compared to 14.4% of the HIV+ individuals37. Again, only genital types of HPV were studied and no specific methods to detect non-genital types of HPV were attempted, which could lead to an underestimation of the HPV prevalence rates. Genital HPV infection is also increased in HIV+ women compared to HIV- women with more women infected with multiple types of HPV, particularly high-risk HPV infections leading to anogenital malignancies38, 39. Women represent a growing percentage of the HIV+ population and indeed the risk factors for oral HPV infection in HIV+ women may differ from HIV+ men, as may the rates of HPV-related oral disease. In addition, the genital tract could serve as a reservoir for current or future oral infection. Clearly, studies are needed to more fully examine the site of oral HPV infection as well as the genotype(s) involved.

Host Defenses against HPV

Humoral

Most immune responses studied in both the oral and genital cavities have been limited to humoral mechanisms. Similar to that reported at other mucosal sites, levels of both serum and mucosal anti-HPV antibodies in HIV+ individuals were found to be normal or elevated but appear to offer no protection from established infection40,41,42. In the study by Hagensee et al41 cervical HPV-16 DNA detection 12 months prior to cervical antibody sampling correlated with the detection of cervical HPV-16-specific IgG (Odds ratio, OR 3.3, confidence intervals, CI,1.4-7.8)41. Although recent studies have detected HPV antibodies in oral fluids43, these studies were cross-sectional in design and did not closely examine the HPV infectious status of the oral cavity.

Cell Mediated Immunity

Although the incidence of HPV infection and disease is higher in patients with cellular immunodeficiencies such as renal transplant recipients and HIV+ individuals7,8, the cellular immune mechanisms that control HPV infection have not been clearly elucidated. Recently, the role of systemic cytokines in the immune response to various pathogens has been investigated44,45. These studies have shown that the immune response can be characterized as a Th1 type (IL-2, IL-12, IFN-γ, IgG1 production) that is involved in control of intracellular (i.e., viral) infections, by the induction of cytolytic activity44. Conversely, a Th2-type response (IL-4, IL-5, IL-10, IgG4, IgA production) is functionally important against extracellular pathogens (i.e., bacteria and parasitic infections) through antibody-mediated mechanisms44. In HIV disease a shift in the Th1/Th2 response has been suggested during progression to AIDS, though this has proved controversial45. Preliminary data have shown that women with abnormal Papanicolou smears or cervical neoplasia have lower systemic IL-2 levels and higher IL-4 and IL-10 than do controls which suggests that HPV disease occurs with a relative decrease in Th1 cytokines and with a relative increase of Th2 cytokines46,47. However, no study of systemic cytokines or local mucosal cytokines in oral HPV infection has been done.

Immune Restoration Due To HAART

The introduction of protease inhibitors and the development of combination highly active anti-retroviral therapy (HAART) in the late 1990's has had a profound impact on HIV disease with the associated decreases in systemic HIV viral loads and increases in CD4+ cells9. This has also been associated with a marked decrease in the risk of many oral opportunistic infections including oral candidiasis, Kaposis' sarcoma, major aphthous ulcers and necrotizing stomatitis13, 14. Paradoxically, recent reports have noted increases in oral pathology consistent with HPV infection in the presence of HAART, which suggests that defense against oral HPV infection is independent of that restored by HAART and may be adversely effected12. Although, many have studied the impact of HAART on systemic immune function, relatively little is known about the reconstitution of mucosal immunity

Summary

Human papillomavirus is a ubiquitous pathogen that infects mucosal surfaces especially the genital tract and oral cavity. The current clinical observation of an increase in oral pathology due to HPV in the HIV+ individual in the setting of active anti-retroviral therapy implies the lack of mucosal immune reconstitution.

Figure 1
Table 1: Site and Type of HPV

Correspondence to

Dr. Kishore Shetty
Associate Professor - Medically Complex Patient Clinic
University of Texas Health Sciences Center
6516 M.D.Anderson Boulevard, Suite #475
Houston Texas 77030
Phone: 713.500.4269

References

1. Coutlee, F., Gravitt, P. E., Richardson H, Hankins C, Franco, E., Lapoints, N., Voyer H, and and the Canadian Women's HIV Study Group. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. J Clin Micro 37, 1852-1857. 1999.
2. Greenstone, H. and Greenspan, JS. HIV infection and oral disease. The Lancet 348, 729-733. 1996.
3. Koutsky, L.A., D.A. Galloway, and K.K. Holmes. 1988. The epidemiology of genital papillomavirus infections. Epidemiol.Rev. 10:122-163.
4. .Praetorius F. HPV-associated diseases of the oral mucosa. Clin Dermatol. 1997; 15. 399-413
5. Chang F, Syrjanen S, and Kellokoski J, Syrjanen K. Human Papillomavirus (HPV) infection and their associations with oral disease. J Oral Pathol Med 20, 305-317. 1991.
6. Laskaris G, Hadjivassiliou M, and Stratgos J. Oral signs and symptoms in 160 HIV-infected patients. J Oral Pathol Med 21, 120-123. 1992.
7. Robinson, W. and Morris, C. Cervical Neoplasia. Pathogenesis, diagnosis and management. Hematology/Oncology Clinics of North America 10, 1163-1176. 1996.
8. Sun, X.-W., Kuhn, L., Ellerbrock, T., Chaisson, M., Bush, T., and Wright, Jr. T. Human papillomavirus infection in women infected with the human immunodeficiency virus. New England Journal of Medicine 337, 1343-1349. 1997.
9. Anonymous. Report of the NIH Panel to define principles of therapy of HIV infection. Ann Intern Med 128, 1057-1078. 1998.
10. Heard, I., Schmitz, V., Costoglioloa, P., Orth, G., and Kazatchkine, M. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 12, 1459-1464. 1998.
11. Orlando G, Fasolo MM, Schiavini M, Signori R, and Cargnel A. Role of highly active antiretroviral therapy in human papillomavirus-inducd genital dysplasia in HIV-1-infected patients. AIDS 13, 424-425. 1999.
12. Leigh I. Oral warts rise dramatically with use of new agents in HIV. HIV Clinician , 7-8. 2000.
13. Greenspan JS. Oral lesions in HIV infection in developed countries. 4th International Workshop on the Oral Manifestations of HIV Infection , 20-20. 2000.
14. Patton LL, McKaig RG, Strauss RP, and Eron Jr JJ. Oral manifestations of HIV in a southeast USA population. Oral Diseases 4, 164-169. 1998.
15. De Villiers, E.-M. 1989. Heterogeneity of the human papillomavirus group. J.Virol. 63:4898-4903.
16. Bouquot JE. Common oral lesions found during a mass screening examination. J Am Dent Assoc 112, 50-57. 1986.
17. Knapp MJ. Oral disease in 181,338 consecutive oral examinations. J Am Dent Assoc 83, 1288-1293. 1971. 14. Itin PH and Lautenschlager S. Viral lesions of the mouth in HIV-infected patients. Dermatology 194, 1-7. 1997.
18. Kellokoski JK, Syranen, S., Chang F, Yliskoski M, and Syrjanen, K. Southern blot hybridization and PCR in detection of oral human papillomavirus (HPV) infections in women with genital HPV infections. J Oral Pathol Med 21, 459-464. 1992.
19. Terai M, Hashimoto K, Yoda K, and Sata T. High prevalence of human papillomvirus in the normal oral cavity of adults. Oral Microbiol Immunol 14, 201-205. 1999.
20. Lawton GM, Rhomas SJ, Schonrock J, Monsour FN, and Frazer, I. H. Human papillomaviruses in normal oral mucosa: a comparison of methods for sample collection. J Oral Pathol Med 21, 265-269. 1992.
21. Holladay EB and Gerald WL. Viral gene detection in oral neoplasms using the polymerase chain reaction. Am J Clin Pathol 100, 36-40. 1993.
22. Schwartz SM, Daling, J. R., Doody, D. R., Wipf, G. C., Carter, J. J., Madeleine, M. M., Mao, E. J., Fitzgibbons, E. D., Huang, S., Beckmann, A. M., McDougall, J. K., and Galloway, D. A. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Nat Cancer Inst 90, 1626-1636. 2000.
23. Paz IB, Cook N, Odom-Maryon T, Xie Y, and Wilczynski S. Human papillomavirus (HPV) in head and neck cancer. Cancer 79, 595-604. 1997.
24. Miller CS and White DK. Human papillomavirus expression in oral mucosa, premalignant conditions and squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathol, Oral Radiol Endod 82, 57-68. 1996.
25. McKaig RG, Baric RS, and Olshan AF. Human papillomavirus and head and neck cancer: Epidemiology and molecular biology. Head & Neck 20, 250-265. 1998.
26. Mineta H, Ogino T Amano H, Ohkawa Y, Araki K, Takebayashi S, and Miura K. Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Research 18, 4765-4768. 1998.
27. Palefsky, J., Silverman Jr S, Abdel-Salaam M, Daniels TE, and Greenspan JS. Association between proliferative verrucous leukoplakia and infection with human papillomavirus type 16. J Oral Pathol Med 24, 193-197. 1995.
28. Itin PH and Lautenschlager S. Viral lesions of the mouth in HIV-infected patients. Dermatology 194. 1-7. 1997
29. Barr CE, Lopez MR, Rua-Dobles A, Miller LK, Mathur-Wagh U, and Turgeon LR. HIV-associated oral lesions: immunologic, virologic and salivary parameters. J Oral Pathol Med 21, 295-298. 1992.
30. Moniaci D, Greco D, Flecchia G, Raiteri R, and Sinicco A. Epidemiology, clinical features, and prognostic value of HIV-1 related oral lesions. J Oral Pathol Med 19, 477-481. 1990.
31. Miroski GW, Hilton JF, Greenspan D, Canchola AJ, MacPhail LA, Mauer T, Berger TG, and Greenspan JS. Association of cutaneous and oral diseases in HIV-infected men. Oral Diseases 4, 16-21. 1998.
32. Hilton JF, Donegan E, Katz MH, Canchola AJ, Fusaro RE, Greenspan D, and Greenspan, JS. Development of oral lesions in human immunodeficiency virus-infected transfusion recipients and hemophiliacs. Am J Epidmiol 145, 164-174. 2000.
33. Shiboski, S., Hilton JF, Neuhaus JM, Canchola AJ, and Greenspan D. Human immunodeficiency virus-related oral manifestations and gender. A longitudinal analysis. Arch Intern Med 156, 2249-2254. 2000.
34. Greenspan D, de Villiers, E. M., Greenspan, JS, de Souza YG, and zur Hausen, H. Unusual HPV types in oral warts in association with HIV infection. J Oral Pathol Med 17, 482-487. 1988.
35. Volter C, He Y, Delius H, Roy-Berman A, Greenspan JS, Greenspan D, and de Villiers, E. M. Novel HPV types present in oral papillomavirus lesions from patients with HIV infection. Int J Cancer 66, 453-456. 1996.
36. Flaitz CM, Nichols CM, Adler-Storthz K, and Hicks, MJ. Intraoral squamous cell carcinoma in human immunodeficiency virus infection. Oral Surgery, Oral Medicine, Oral Pathol, Oral Radiol Endod 80, 55-62. 1995.
37. Coutlee, F., Trottier A, Ghattas G, Leduc R, Toma E, Sanche G, Rodrigues I, Turmel B, Allaire G, and Ghadirian P. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis 24, 23-31. 1996.
38. Kellokoski JK, Syranen, S., Syrjanen, K., and Yliskoski M. Oral mucosa changes in women with genital HPV infection. J Oral Pathol Med 19, 142-148. 1990.
39. Kellokoski JK, Syranen, S., Yliskoski M, and Syrjanen, K. Dot blot hybridization in detection of human papillomvirus (HPV) infection in the oral cavity of women with genital HPV infections. Oral Microbiol Immunol 7, 19-23. 1992.
40. McGhee, J. R., Mestecky, J., Derzbaugh, M. T., Eldridge, J. H., Jirasawa, M., and Kiyono, H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10(2), 75-88. 1992.
41. Hagensee, M. E., Koutsky, L. A., Lee, S.-K., Kuypers, J., Kiviat, N. B., and Galloway, D. A. Detection of cervical antibodies against HPV 16 in college-aged women. Journal of Infectious Diseases 181, 1234-1239. 2000.
42. Carter, J. J. and Galloway, D. A. Humoral immune response to human papillomavirus infection. Clinics In Dermatology 15, 249-259. 1997.
43. Marais DJ, Best, J., Rose, R. and Keating, P. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J Med Virol. 65: 149-154. 2001.
44. Romagnani, S. Lymphokine production by human T cells in disease states. Annu.Rev.Immunol. 12, 227-257. 1994.
45. Clerici, E., Fusi ML, Ruzzante S, Piconi S, Biasin M, Arienti D, Trabattoni D, and Villa ML. Type 1 and Type2 cytokines in HIV infection - a possible role in apoptosis and disease progression. Annals of Medicine , 185-188. 1997.
46. Tsukui, T., Hildesheim, A., Schiffman, M., Lucci, J., contois, D., and Lawler, P. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology. Cancer Research 56, 3967-3974. 1996.
47. Clerici, M., M. Merola, E. Ferrario, D. Trabattoni, M.L. Villa, B. Stefanon, D.J. Venzon, G.M. Shearer, G. De Palo, and E. Clerici. 1997. Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection. J.Natl.Cancer Inst. 89:245-250.
48. Gravitt, P. E., Peyton, C. L., Apple, R. J., and Wheeler, C. M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Micro 36, 3020-3027. 1998.

Author Information

Kishore Shetty, DDS
Medically Complex Patient Clinic, University of Texas Health Sciences Center

Janet Leigh, DMD
Department of General Dentistry, Louisiana State University Health Sciences Center

Download PDF

Your free access to ISPUB is funded by the following advertisements:

 

BACK TO TOP
  • Facebook
  • Google Plus

© 2013 Internet Scientific Publications, LLC. All rights reserved.    UBM Medica Network Privacy Policy